The Correlation And Expression Of Ki67before And After Neochemtherapy In Breast Cancer

Neoadjuvant therapy is treatment given before primary therapy. A woman may receive neoadjuvant chemotherapy for breast cancer to shrink a tumor that is inoperable in its current state, so it can be surgically removed. A woman whose tumor can be removed by mastectomy may instead receive neoadjuvant therapy to shrink the tumor enough to allow breast-conserving surgery。 Antigen Ki-67also known as Ki-67or Mki67is a protein that in humans is encoded by the Mki67gene (antigen identified by monoclonal antibody Ki-67)., and may be necessary for cellular proliferation. Ki-67is an excellent marker to determine the growth fraction of a given cell population. The fraction of Ki-67-positive tumor cells (the Ki-67labeling index) is often correlated with the clinical course of cancer.There isn’t certain evidence whether ki67is the mark for efficency in neoadjuvent chemotherapy of breast cancer or not.The aim of this study is to identify it’s new effection with fifty case,compared the response before and after neoadjuvant chemotherapy.MethodFifty cases are admitted in third affiliated hospital of kunming medical university from sem,2010to jun,2012,whose cancer stage between Ⅱ—Ⅲ,and their age between27～65, the middle age is46. The majority of the participants were aged≥40years (82%) and postmenopausal (18%).All of them are dignosed by initial biopsy. The program of chemotherapy is:cyclophosphamide+adriamycin+Fluorouracil. Analyses were performed using SAS version9.2(SAS Institute, Inc., Cary, NC). Two sided p-values were calculated. A Bonferroni adjustment to account for multiple testing was applied to define the threshold for statistical significance as p<0.003(=0.05/14loci).ResultThe rate efficiency in fifty cases is76%,and the PCR is2%. Two sided p-values were calculated. A Bonferroni adjustment to account for multiple testing was applied to define the threshold for statistical significance as p≤0.003(=0.05/14loci). The neoadjuvant setting is a useful model for investigating the value of Ki67as a predictive and prognostic factor. Some neoadjuvant studies have investigated Ki67in relation to complete pathological response (pCR), and one has examined its association with disease progression during neoadjuvant therapy. The majority of studies investigating pCR have identified a high Ki67proliferation rate as a predictive factor for a higher rate of pCR, but the only study that has examined progression during neoadjuvant chemotherapy found that patients in whom progression occurred had a higher proliferation rate than those who responded to chemotherapy.